Therapeutic equivalence: Concept and evidence levels;Equivalencia terapéutica: Concepto y niveles de evidencia

Medicina Clinica

Volumn 129, Issue 19, 2007, Pages 736-745

  Delgado Sánchez, Olga ^a   Latorre, Francesc Puigventós ^a   Blanco, Manel Pinteño ^b   Bosch, Pere Ventayol ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Hospital Comarcal d'Inca   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOEQUIVALENCE; CLINICAL PRACTICE; HUMAN;

EID: 37149054758     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13113299     Document Type: Article

References (69)

1. Pocock S. Clinical trials: a practical approach. New York: John Wiley: 1996.
2. Committee for Medicinal Products for Human Use (CMPH). Guideline on the choice of the non-inferiority margin. EMEA/CPMP/EWP/2158/99. The European Agency for the Evaluation of Medicines Products EMEA; 27 July 2005 [consultado 27/04/2007]. Disponible en: http://www.emea.eu.int
3. Gotzsche P. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA. 2006;295:1172-4.
4. Ley 29/2006 de Garantías y Uso Racional de los Medicamentos y Productos Sanitarios. BOE no. 178, de 27 de julio de 2006; p. 28122-65.
5. Choice of control group and related issues in clinical trials. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. E10 Guideline. Food and Drug Administration (FDA), May 2001 [consultado 28 Abril 2007]. Disponible en: http://www.fda.gov/cder/guidance/4155fnl.htm
6. Tie-Hua N. Choice of delta in equivalence testing. Drug Inf J. 2001;35:1517-27.
7. Sociedad Española de Farmacéuticos Atención Primaria (SEPAP). Bioequivalencia: hablemos del ± 20%. Boletín de Uso Racional del Medicamento. 2005;13:1-4.
8. Snapinn S. Noninferiority trials. Curr Control Trials Cardiovasc Med. 2000;1:19-21.
9. Cobo E. Elección del grupo control. Distintas hipótesis, distinta metodología. ICB Digital. 2003;(12):2-5.
10. Gomberg-Maitland M, Frison L, Halperin J. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concept linked to quality. Am Heart J. 2003;146:398-403.
11. EMEA/CPMP/EWP/482/99. Committee for Medicinal Products for Human Use (CMPH). Points to consider on switching between superiority and non-inferiority. The European Agency for the Evaluation of Medicinal Products EMEA; 27 July 2000 [consultado 27 Abril 2007]. Disponible en: http://www.eudra.org/emea.html
12. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-76.
13. Jones B, Jarvis P, Lewis J, Ebbutt A. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313:36-9.
14. Argimon J. La ausencia de significación estadística en un ensayo clínico no significa equivalencia terapéutica. Med Clin (Barc). 2002;118: 701-3.
15. Wiens B, Iglewicz B. Testing noninferiority of resonse rates for regulatory filings using transformations. Drug Inf J. 2001;35:1165-71.
16. Committee for Proprietary Medicinal Products (CPMP). Choice of delta. The European Agency for the Evaluation of Medicinal Products (EMEA) 23 Septembrer 1999 [consultado 27 04 2007]. Disponible en http:// www.eudra.org/emea.html
17. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-23.
18. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med. 1997;337:1124-30.
19. Ware JH, Antman EM. Equivalence trials. N Engl J Med. 1997;337:1159-61.
20. Rex JH, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE, Washburn RG, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331:1325-30.
21. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-47.
22. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements. Clinical considerations for accelerated and traditional approval. U.S. Department of Health and Human Services. Rockville: Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER); October 2002.
23. Guidance for industry: developing antimicrobial drugs: general considerations for clinical trial (Draft). Rockville: Food and Drug Administration Divission of Anti-Infective Drug Products; 1998.
24. Moran J, Solomon P. The interpretation of lack of evidence of a difference in efficacy: equivalence trials and the treatment of fungal infections. Critical Care and Resuscitation. 2003;5:216-23.
25. Tygacil (tigecycline) injection. CDER archive. U.S. Food and Drug Administration (FDA) [consultado 01 Mayo 2007]. Disponible en: http://www.fda.gov/cder/
26. Cubicin (daptomycin) injecion. CDER archive. U.S. Food and Drug Administration (FDA) [consultado 01 Mayo 2007]. Disponible en: http://www.fda.gov/cder/
27. Chung-Ying Zee B. Planned equivalence or noninferiority trials versus unplanned noninferiority claims: are they equal? J Clin Oncol. 2006;24:1026-8.
28. Aras G. Superiority, noninferiority, equivalence, and bioequivalence-revisited. Drug Information Journal. 2001;35:1157-64.
29. Djulbegovic B, Clarke M. Scientific and ethical issues in equivalence trials. JAMA. 2001;285:1206-8.
30. Gallant DE, DeJesús E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60.
31. Korn E, Hunsberger S, Freidlin B, Smith M, Abrams J. Preliminary data release for randomized clinical trials of noninferiority: a new proposal. J Clin Oncol. 2005;23:5831-6.
32. Greene W, Concato J, Feinstein A. Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med. 2000;132:715-22.
33. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295:1147-51.
34. Piaggio G, Elbourne D, Altman D, Pocock S, Evans S, Group FTC. Reporting of noninferiority and equivalence randomized trials. An extension of the CONSORT statement. JAMA. 2006;295:1152-60.
35. Pater C. Equivalence and noninferiority trials-are they viable alternatives for registration of new drugs? (III). Curr Control Trials Cardiovasc Med. 2004;5:8-15.
36. Miravitlles M, Torres A. No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest. 2004;125:811-3.
37. Song F, Altman D, Glenny A, Deeks J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326:472-6.
38. Moreno-González A y Grupo de trabajo FUINSA sobre guías terapéuticas. Guías terapéuticas, ¿qué puede esperarse de ellas? Med Clin (Barc). 2005;125:421-2.
39. Jovel AJ, Navarro-Rubio MD. Evaluación de la evidencia científica. Med Clin (Barc). 1995;105:740-3.
40. Pinteño M, Martínez-López I, Delgado O. Equivalentes terapéuticos: concepto y niveles de evidencia. El Farmacéutico Hospitales. 2006:14-8.
41. Van de Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet. 1999;354:716-22.
42. Green W. A randomized double-blind multicenter phase III study of fixed-dose single-administration PEGF versus daily filgrastim in patients receiving myelosupressive chemotherapy. Ann Oncol. 2003;14:29-35.
43. Holmes F. Blinded, randomized, multicenter study to evaluate single administration PEGF once per cycle versus dayly filgrastim as an adjunt to chemotherapy in patients with high-risc stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727-31.
44. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo and tolterodine-controlled trial of the once-daily antimuscarinicagent solifencin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303-10.
45. Argimon J. El intervalo de confianza, algo más que un valor de significación estadística. Med Clin (Barc). 2002;118:382-4.
46. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc. 2002;11:182-8.
47. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485.
48. European Atosiban Study Group. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study. Acta Obstetr Gynecol Scand. 2001;80:413-22.
49. French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. Eur J Obstet Gynecol Reprod Biol. 2001;98:177-85.
50. Moutquin JM, Sherman D, Cohen H, Mohide PT, Hochner-Celnikier D, Fejgin M, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol. 2000;182:1191-9.
51. Kragh-Sorensen P, Muller B, Andersen JV, Buch D, Stage KB. Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. J Clin Psychopharmacol. 1995;15 4 Suppl 2:24-30.
52. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006;151:273-81.
53. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor a blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62 Suppl 2:13-6.
54. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
55. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
56. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-9.
57. Pitt B, Remme W, Zannad F, Neaton J, Martínez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction (EPHESUS). N Engl J Med. 2003;348:1309-21.
58. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
59. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953-64.
60. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and longterm clinical outcomes. Clin Ther. 2002;24:639-52.
61. Esplugues JV, Martí-Cabrera M, Ponce J. Seguridad de la utilización de inhibidores de la bomba de protones. Med Clin (Barc). 2006;127:790-5.
62. Gisbert JP, Calvet X, Gomollon F, Mones J, Grupo Conferencia Española de Consenso sobre Helicobacter pylori. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la II Conferencia Española de consenso. Med Clin (Barc). 2005;125:301-16.
63. Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane Collaboration meta-anlysis of randomised controlled trials. Mayo Clin Proc. 2007;82:286-96.
64. Anónimo. L'année du médicament: quand la publicité masque l'absence de progrès thèrapeutique. Revue Prescrire. 2007;280:140-9.
65. Catalán A, Recalde J, Aizpurua I, Aza M, Erviti J. La experiencia del Comité Mixto de Evaluación de Nuevos Medicamentos (CMENM). Farm Aten Primaria. 2006;4 Extra:7-16.
66. Alegre EJ. Evaluación de nuevos fármacos. Revista Oficial de la Sociedad Andaluza de Farmacéuticos de Hospital. 2005;1:26-34.
67. Puigventos F, Ventayolo P, Pinteno M, Delgado O, Campoamor F, Serra J. Futuro de la selección de medicamentos en el hospital. Todo Hospital 2005;221:634-8.
68. Soto J. Valor terapéutico añadido de los medicamentos, ¿qué es, cómo se evalúa y cuál debería ser su papel en política farmacéutica? An Med Interna (Madrid). 2005;22:39-42.
69. GENESIS Grupo de trabajo de la SEFH. Programa madre de ayuda a la redacción de informes de evaluación de un nuevo medicamento. Manual de procedimientos. Versión 3.0. Septiembre 2005 [publicación electrónica] [consultado 27 Abril 2007]. Disponible en: http://genesis.sefh.es